AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (5.5 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice

Wen Du1,2Mengyu Yang2,3Terresa Kim2,3Sol Kim2,3Drake W. Williams2,3Maryam Esmaeili2,3Christine Hong4Ki-Hyuk Shin2,5Mo K. Kang2,5No-Hee Park2,5,6Reuben H. Kim2,3,5( )
State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases & Department of Prosthodontics, West China Hospital of Stomatology, Sichuan University, Chengdu, China
The Shapiro Family Laboratory of Viral Oncology and Aging Research, Los Angeles, USA
Section of Restorative Dentistry, UCLA School of Dentistry, Los Angeles, USA
Department of Orofacial Sciences, UCSF School of Dentistry, San Francisco, USA
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, USA
David Geffen School of Medicine at UCLA, Los Angeles, USA
Show Author Information

Abstract

Bacterial infection is a common finding in patients, who develop medication-related osteonecrosis of the jaw (MRONJ) by the long-term and/or high-dose use of anti-resorptive agents such as bisphosphonate (BPs). However, pathological role of bacteria in MRONJ development at the early stage remains controversial. Here, we demonstrated that commensal microbiota protects against MRONJ development in the pulp-exposed periapical periodontitis mouse model. C57/BL6 female mice were treated with intragastric broad-spectrum antibiotics for 1 week. Zoledronic acid (ZOL) through intravenous injection and antibiotics in drinking water were administered for throughout the experiment. Pulp was exposed on the left maxillary first molar, then the mice were left for 5 weeks after which bilateral maxillary first molar was extracted and mice were left for additional 3 weeks to heal. All mice were harvested, and cecum, maxilla, and femurs were collected. ONJ development was assessed using μCT and histologic analyses. When antibiotic was treated in mice, these mice had no weight changes, but developed significantly enlarged ceca compared to the control group (CTL mice). Periapical bone resorption prior to the tooth extraction was similarly prevented when treated with antibiotics, which was confirmed by decreased osteoclasts and inflammation. ZOL treatment with pulp exposure significantly increased bone necrosis as determined by empty lacunae and necrotic bone amount. Furthermore, antibiotics treatment could further exacerbate bone necrosis, with increased osteoclast number. Our findings suggest that the commensal microbiome may play protective role, rather than pathological role, in the early stages of MRONJ development.

References

1

Chen, J. S. & Sambrook, P. N. Antiresorptive therapies for osteoporosis: a clinical overview. Nat. Rev. Endocrinol. 8, 81–91 (2011).

2

Marx, R. E., Sawatari, Y., Fortin, M. & Broumand, V. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J. Oral Maxillofac. Surg. 63, 1567–1575 (2005).

3

Ruggiero, S. L. et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw-2014 update. J. Oral Maxillofac. Surg. 72, 1938–1956 (2014).

4

Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125–1132 (2011).

5

Martins, A. S. et al. Relevant factors for treatment outcome and time to healing in medication-related osteonecrosis of the jaws—a retrospective cohort study. J. Craniomaxillofac. Surg. 45, 1736–1742 (2017).

6

Vahtsevanos, K. et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J. Clin. Oncol. 27, 5356–5362 (2009).

7

Soundia, A. et al. Zoledronate impairs socket healing after extraction of teeth with experimental periodontitis. J. Dent. Res. 97, 312–320 (2018).

8

Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase Ⅲ trials in cancer patients with bone metastases. Ann. Oncol. 23, 1341–1347 (2012).

9

Yamazaki, T. et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int. J. Oral Maxillofac. Surg. 41, 1397–1403 (2012).

10

Aghaloo, T. L. et al. Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat. J. Bone Miner. Res. 26, 1871–1882 (2011).

11

Ficarra, G. et al. Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment. J. Clin. Periodontol. 32, 1123–1128 (2005).

12

Boonyapakorn, T., Schirmer, I., Reichart, P. A., Sturm, I. & Massenkeil, G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol. 44, 857–869 (2008).

13

Kim, T. et al. Removal of pre-existing periodontal inflammatory condition before tooth extraction ameliorates medication-related osteonecrosis of the jaw-like lesion in mice. Am. J. Pathol. 188, 2318–2327 (2018).

14

Mawardi, H. et al. Sinus tracts-an early sign of bisphosphonate-associated osteonecrosis of the jaws? J. Oral Maxillofac. Surg. 67, 593–601 (2009).

15

Kang, B. et al. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. J. Bone Miner. Res. 28, 1631–1640 (2013).

16

Aguirre, J. I. et al. Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J. Bone Miner. Res 27, 2130–2143 (2012).

17

Lopez-Jornet, P. et al. Perioperative antibiotic regimen in rats treated with pamidronate plus dexamethasone and subjected to dental extraction: a study of the changes in the jaws. J. Oral Maxillofac. Surg. 69, 2488–2493 (2011).

18

Nair, P. N. On the causes of persistent apical periodontitis: a review. Int. Endod. J. 39, 249–281 (2006).

19

Stashenko, P., Teles, R. & D’Souza, R. Periapical inflammatory responses and their modulation. Crit. Rev. Oral Biol. Med. 9, 498–521 (1998).

20

Katsarelis, H., Shah, N. P., Dhariwal, D. K. & Pazianas, M. Infection and medication-related osteonecrosis of the jaw. J. Dent. Res. 94, 534–539 (2015).

21

Kos, M. et al. Pamidronate enhances bacterial adhesion to bone hydroxyapatite. Another puzzle in the pathology of bisphosphonate-related osteonecrosis of the jaw? J. Oral Maxillofac. Surg. 71, 1010–1016 (2013).

22

Sedghizadeh, P. P. et al. Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy. J. Am. Dent. Assoc. 140, 1259–1265 (2009).

23

Ripamonti, C. I. et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann. Oncol. 20, 137–145 (2009).

24

Sedghizadeh, P. P. et al. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J. Oral Maxillofac. Surg. 66, 767–775 (2008).

25

Williams, D. W. et al. Indigenous microbiota protects against inflammation-induced osteonecrosis. J. Dent. Res. 99, 676–684 (2020).

26

Song, M. et al. Development of a direct pulp-capping model for the evaluation of pulpal wound healing and reparative dentin formation in mice. J Vis Exp (2017).

27

Song, M. et al. Preexisting periapical inflammatory condition exacerbates tooth extraction-induced bisphosphonate-related osteonecrosis of the jaw lesions in mice. J. Endod. 42, 1641–1646 (2016).

28

Gordon, H. A. & Pesti, L. The gnotobiotic animal as a tool in the study of host microbial relationships. Bacteriol. Rev. 35, 390–429 (1971).

29

Dimopoulos, M. A. et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann. Oncol. 20, 117–120 (2009).

30

Reikvam, D. H. et al. Depletion of murine intestinal microbiota: effects on gut mucosa and epithelial gene expression. PLoS ONE 6, e17996 (2011).

31

Graves, D. T., Kang, J., Andriankaja, O., Wada, K. & Rossa, C. Jr Animal models to study host-bacteria interactions involved in periodontitis. Front. Oral Biol. 15, 117–132 (2012).

32

Abe, T. & Hajishengallis, G. Optimization of the ligature-induced periodontitis model in mice. J. Immunol. Methods 394, 49–54 (2013).

33

Williams, D. W. et al. Impaired bone resorption and woven bone formation are associated with development of osteonecrosis of the jaw-like lesions by bisphosphonate and anti-receptor activator of NF-kappaB ligand antibody in mice. Am. J. Pathol. 184, 3084–3093 (2014).

34

Kozutsumi, R. et al. Zoledronic acid deteriorates soft and hard tissue healing of murine tooth extraction sockets in a dose-dependent manner. Calcif. Tissue Int. 110, 104–116 (2022).

35

Sjogren, K. et al. The gut microbiota regulates bone mass in mice. J. Bone Miner. Res. 27, 1357–1367 (2012).

36

Kuroshima, S., Go, V. A. & Yamashita, J. Increased numbers of nonattached osteoclasts after long-term zoledronic acid therapy in mice. Endocrinology 153, 17–28 (2012).

37

Lakschevitz, F. S. et al. Identification of neutrophil surface marker changes in health and inflammation using high-throughput screening flow cytometry. Exp. Cell Res. 342, 200–209 (2016).

38

Tseng, H. C. et al. Bisphosphonate-induced differential modulation of immune cell function in gingiva and bone marrow in vivo: role in osteoclast-mediated NK cell activation. Oncotarget 6, 20002–20025 (2015).

39

Weinstein, R. S., Roberson, P. K. & Manolagas, S. C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N. Engl. J. Med. 360, 53–62 (2009).

40

Ferrari-Lacraz, S. & Ferrari, S. Do RANKL inhibitors (denosumab) affect inflammation and immunity? Osteoporos. Int. 22, 435–446 (2011).

41

Merida, S. et al. Bevacizumab diminishes inflammation in an acute endotoxin-induced Uveitis model. Front. Pharm. 9, 649 (2018).

42

Kakehashi, S., Stanley, H. R. & Fitzgerald, R. J. The effects of surgical exposures of dental pulps in germ-free and conventional laboratory rats. Oral Surg. Oral Med. Oral Pathol. 20, 340–349 (1965).

43

Matsumoto, T. et al. Factors affecting successful prognosis of root canal treatment. J. Endod. 13, 239–242 (1987).

44

Mawardi, H. et al. A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw. J. Dent. Res. 90, 1339–1345 (2011).

45

Bouxsein, M. L. et al. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25, 1468–1486 (2010).

International Journal of Oral Science
Article number: 16
Cite this article:
Du W, Yang M, Kim T, et al. Indigenous microbiota protects development of medication-related osteonecrosis induced by periapical disease in mice. International Journal of Oral Science, 2022, 14: 16. https://doi.org/10.1038/s41368-022-00166-4

217

Views

0

Downloads

12

Crossref

12

Web of Science

11

Scopus

Altmetrics

Received: 02 December 2021
Accepted: 21 February 2022
Published: 21 March 2022
© The Author(s) 2022

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Return